Products Affected - Description
Phenazopyridine oral tablet, Marlex
100 mg tablets, 6 count (NDC 10135-0199-78) - discontinued
100 mg tablets, 30 count (NDC 10135-0199-30) - discontinued
100 mg tablets, 100 count (NDC 10135-0621-01)
100 mg tablets, 1000 count (NDC 10135-0199-01) - discontinued
100 mg tablets, 1000 count (NDC 10135-0199-10) - discontinued
Reason for the Shortage
- Amneal Pharmaceuticals, Avkare, SDA Laboratories discontinued phenazopyridine tablets.
- Gemini Laboratories has new NDC numbers for Pyridium products. Gemini has product available.
- Marlex could not provide a reason for the shortage. They have discontinued all but the 100 count presentations.
Pyridium oral tablet, Gemini Laboratories
100 mg, 100 count (NDC 60846-0501-01)
200 mg, 100 count (NDC 60846-0502-01)
Estimated Resupply Dates
Marlex has phenazopyridine 100 mg tablets in 100 count on back order and the company estimates a release date of early-August 2016. The 100 count bottles will have a new NDC (NDC 10135-0621-01) upon release.
July 19, May 13, February 10, 2016; December 9, September 10, July 1, June 30, May 20, April 8, February 11, 2015; December 10, November 20, 2014, University of Utah, Drug Information Service. Copyright 2016, Drug Information Service, University of Utah, Salt Lake City, UT.
This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.
« Back to Drug Shortage Product Bulletins